Australia - Opthea (OPT) CEO & Managing Director, Megan Baldwin: Executive Series 21 Sep 16: CommSecTV

CommSecTV

Published on Sep 22, 2016

Tom Piotrowski speaks with Opthea (OPT) CEO & Managing Director, Megan Baldwin about the results of its Phase 2 study of its OPT-302 drug aimed at treating the Wet AMD eye disease.

http://www.4-traders.com/OPTHEA-LTD-25398924/ 

www.opthea.com/

Welcome to the new Opthea Twitter

— Opthea (@Opthea1) December 19, 2012